Related references
Note: Only part of the references are listed.The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
Hirotoshi Echizen
CLINICAL PHARMACOKINETICS (2016)
Letter: vonoprazan, a long-lasting acid suppressor of the gastric H plus , K plus -ATPases with - implications for renal H plus , K plus -ATPases
N. R. Srinivas
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase
D. R. Scott et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
K. Ashida et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology
L. Lundell et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese
Mitsushige Sugimoto et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori
Kazunari Murakami et al.
GASTROENTEROLOGY (2014)
Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole
S. Sahara et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Gastric carcinoids after long-term use of a proton pump inhibitor
C. S. Jianu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin
E. A. Marcus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor
Constantin S. Jianu et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
Development of a Novel, Fully-Automated Genotyping System: Principle and Applications
Shun-ichi Suzuki et al.
SENSORS (2012)
Long-Term Acid Inhibition: Benefits and Harms
Bojan Tepes
DIGESTIVE DISEASES (2011)
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Edward Sheen et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking
Margareta Ramsjo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases
Yasunobu Hori et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population
Katsuyoshi Sugimoto et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy
Mitsushige Sugimoto et al.
HELICOBACTER (2007)
Cytochrome P4502C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis
Masashi Kawamura et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients
Mateusz Kurzawski et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Influence of CYP2C19 polymorphism and helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection
T Furuta et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2005)
Comparison of an increased dosage regimen of rabcprazolc versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P4502C19 genotypes
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Novel approaches to the pharmacological blockade of gastric acid secretion
ME Parsons et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, 5-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects
M Hassan-Alin et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
The macrolide antibiotics: A pharmacokinetic and pharmacodynamic overview
R Jain et al.
CURRENT PHARMACEUTICAL DESIGN (2004)
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status
M Sugimoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism
M Kawamura et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH
N Shirai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis
K Adachi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2001)
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
T Furuta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
